Curis Inc. (CRIS) had a rough trading day for Tuesday November 12 as shares tumbled 6.85%, or a loss of $-0.1 per share, to close at $1.36. After opening the day at $1.43, shares of Curis Inc. traded as high as $1.48 and as low as $1.29. Volume was 389,951 shares over 799 trades, against an average daily volume of n/a shares and a total float of 33.2 million.
As a result of the decline, Curis Inc. now has a market cap of $45.16 million. In the last year, shares of Curis Inc. have traded between a range of $2.90 and $0.60, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis Inc. is based out of Lexington, MA and has some 31 employees. Its CEO is James E. Dentzer.
Curis Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.